Endurance champion triumphs in grueling 7 Emirates Challenge
Abu Dhabi, UAE – In an extraordinary feat of endurance, British expat and Dubai-based consultant Harry Amos has successfully completed the 7 Emirates Challenge in record-breaking time, 5 days, 21 hours, and 30 minutes. Supported by M42, a global health champion powered by artificial intelligence (AI) and technology, Healthpoint and Mubadala Health Dubai, Harry was backed by a dedicated team of expert physiotherapists who provided crucial rehabilitation and recovery support throughout his journey.
Harry embarked on the 7 Emirates Challenge on February 1, determined to complete the grueling 630 kilometers run across the UAE, from Fujairah to the UAE-Saudi Arabia border, in under six days. More than a test of endurance, the challenge aimed to raise awareness about diabetes, making his achievement even more impactful. Despite battling exhaustion, he pushed his limits with the support of the M42 group, ultimately finishing the challenge successfully. After completing the run, he visited Healthpoint for a recovery session and a celebratory ceremony.
'This journey has been one of the toughest challenges of my life but knowing that I was running for a cause bigger than myself kept me going,' said Harry, 'I'm incredibly grateful to M42, Healthpoint and Mubadala Health Dubai for their unwavering support in ensuring I stayed strong and injury-free throughout this challenge. I hope that I have inspired others to be mindful of their physical health and to keep moving.'
With an estimated 1.6 million UAE residents at risk of type 2 diabetes by 2031, Harry and M42's group mission was more than endurance, it was a call for awareness and prevention.
Dr. Hasan Baydoun, Consultant Orthopedic Surgeon and Head of the Orthopedic Department at Healthpoint and Mubadala Health Dubai, said, 'We are thrilled to have played a role in Harry's extraordinary success. Our expert team of physiotherapists and sports medicine experts was on hand to assist him throughout every stage of his journey, ensuring he remained strong and injury-free. At M42, we are committed to spreading awareness around health and well-being, while delivering world-class care to our patients and the community.'
About Healthpoint
Healthpoint, part of the M42 group, is a multi-specialty hospital based in Abu Dhabi. The hospital includes a wide range of primary and specialty care services, and five centers of excellence: Obesity Management, Metabolic and Bariatric Surgery Center of Excellence, Dentistry, Endoscopy, Orthopedics & Sports Medicine, Physiotherapy & Rehabilitation.
Focusing on a carefully defined set of medically integrated services and practices, Healthpoint's patient-centered approach is organized around medical conditions over the full cycle of care and delivered in integrated practice units (IPUs).
Committed to elevating patient care to the highest standards, Healthpoint has been recognized by numerous renowned international awarding and accrediting bodies. These include the Commission on Accreditation of Rehabilitation Facilities (CARF International), the Joint Commission International (JCI), the Australian Council on Healthcare Standards International (ACHSI), and the American Surgical Review Corporation (SRC).
About Mubadala Health Dubai
Mubadala Health Dubai is a specialty clinic and day surgery center. Established in 2022, it is the first of M42's strategic expansions outside of Abu Dhabi. It provides comprehensive diagnostic services with international standards for adults and children and a continuum of care for communities in Dubai.
Located in Sunset Mall, Jumeirah 3, Mubadala Health Dubai brings a multidisciplinary model of care delivered through a western-board certified medical team from over 30 clinical specialties across M42's network of world-class healthcare assets, including Imperial College London Diabetes Centre and Cleveland Clinic Abu Dhabi.
The 125,000-square foot state-of-the-art facility includes medical and pediatric specialty clinics, a day surgery center, 96 consultation rooms, four operating rooms, two endoscopy suites, as well as an in-house laboratory, in-house pharmacy, a radiology department, dedicated rehabilitation gyms, and dedicated procedure rooms. It also offers a one-of-a-kind post-operative lounge where patients receive comprehensive education from the multidisciplinary team after surgery to optimize their discharge.
Mubadala Health Dubai is on Twitter, Instagram, Facebook and LinkedIn with the handle: @mubadalahealthdubai
About M42
M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally.
Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.
For media inquiries or interview opportunities, please contact:
Maroun Farah
Email: mfarah@webershandwick.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
3 hours ago
- Khaleej Times
No more insulin injections for diabetes patients? UAE doctors explain cell-based treatment
Many diabetic patients abroad have said goodbye to insulin injections or now use them less frequently and in lower doses, according to doctors who noted patients recovered after undergoing a simple surgical procedure to transplant pancreatic cells. "50 per cent of patients with Type 1 diabetes — who typically rely on insulin injections — have been cured through 'islet cell transplantation'," Dr Tahra Abdalla Al Ali, a pediatrician based in the UAE, told Khaleej Times. "This has cured people of their pancreas's inability to produce insulin. Patients will no longer depend on insulin as they look forward to a future without constant insulin management.' Dr Al Ali noted, 'In 25 cases, pancreatic cells were transplanted; and the success rate for this group was 85 per cent. Of the patients, 50 per cent completely stopped using medication. The remaining group members use injections at lower doses and less frequently.' Stay up to date with the latest news. Follow KT on WhatsApp Channels. This treatment, which aims to benefit all patient groups, initially targeted individuals over the age of 20 who suffered from complications of diabetes and had difficulty maintaining healthy levels for an extended period. Procedure explained Dr Al Ali said islet cell transplantation involves transplanting pancreatic cells extracted from donors and studying them in specialised laboratories. Once the safety of these samples is confirmed, they are injected into the patient using a catheter-like method through the skin into a vein and then transplanted onto the liver. 'The transplanted cells help restore and regulate blood sugar levels in patients with type 1 diabetes, preventing severe, life-threatening hypoglycemia episodes and allowing patients to eliminate their daily insulin injections,' she added. Simple and safe The procedure is considered an alternative to the complete pancreas transplant to avoid surgical complications, including organ rejection and bleeding. It is regarded as a safe and simple treatment method. The Emirates Health Services (EHS), in collaboration with the University of Chicago, is working to treat patients from the UAE either abroad or by bringing experts to the country to provide care. Only for Type 1 diabetes The procedure is used exclusively for patients with Type 1 diabetes, where the main issue is the destruction of insulin-producing beta cells, Dr Patanjali Panduranga, endocrinologist at Aster Hospital, explained. It is not considered a treatment for Type 2 diabetes, where insulin resistance is the primary problem. However, some early studies are exploring its use in selected cases of insulin-dependent type 2 diabetes, although this remains under investigation. He noted the US Food and Drug Administration (FDA) approved islet cell transplantation in 2023 for adults with Type 1 diabetes who experienced severe hypoglycemia or poor glucose control despite intensive insulin therapy. Limitations remain 'Although the procedure has shown promising results, including insulin independence in up to 50 per cent of recipients, its broader clinical use remains limited due to the need for lifelong immunosuppression and the scarcity of suitable donor cells,' said Dr Panduranga. Dr Arvind Gaddameedi, another endocrinologist at Aster Clinic, explained that the success of islet cell transplantation depends on two key factors, safety and sustainability. Unlike full organ transplants, this procedure involves a 30-minute infusion under local anesthesia, making it accessible even to high-risk patients. However, challenges remain. One of the challenges is the availability of donor cells. While organ donation rates vary globally, innovations in islet cell processing, cryopreservation, and even stem cell-derived islets, currently under trial, may soon expand accessibility. 'These developments represent a new dawn in diabetes care. While not yet a first-line treatment, islet cell transplantation is a vital option for patients struggling with the demands of insulin therapy. As research progresses, improvements in immunosuppression, donor matching, and cell supply are expected to make this treatment more widely available.'
Zawya
a day ago
- Zawya
IntelliDent AI and Woxsen University forge strategic alliance to advance AI research, leadership & innovation in healthcare
IntelliDent AI, a Dubai-based healthtech company at the forefront of artificial intelligence solutions in dentistry, has signed a Memorandum of Understanding (MoU) with Woxsen University's AI Research Centre, Hyderabad, India. The five-year strategic partnership aims to drive collaborative innovation through joint research, live project exposure, and advanced technical training. This collaboration is designed to fuel co-innovation, AI-driven entrepreneurship, and cutting-edge research in digital healthcare. Under this agreement, IntelliDent AI and Woxsen University will engage in joint academic-industry initiatives focused on AI-driven healthcare solutions, consultancy-based projects, and the commercialization of technology innovations. The MoU outlines cooperation in the following key areas: Real-World AI Projects: IntelliDent will provide students from Woxsen's AI Research Centre hands-on exposure to live, real-time projects from the healthcare domain—preparing them to address real-world challenges with AI-driven solutions. Joint Research & Publications: Both institutions will collaborate on research grants, white papers, product prototypes, and academic publications that shape the future of medical technology. Entrepreneurship & Product Commercialization: Special focus will be placed on developing products from ideation to market readiness, with guidance on building startups and commercializing AI health tech solutions. Cross-Training & Knowledge Exchange: Faculty and industry professionals will exchange expertise in best practices, fostering a culture of mutual growth and continuous innovation. Strategic Awareness Initiatives: Co-hosted awareness programs, leadership bootcamps, and innovation challenges will promote ethical AI, responsible leadership, and entrepreneurship across emerging markets. Speaking on the occasion, Mr. Affaan Shaikh, Founder and CEO of IntelliDent AI, stated: 'This MoU with Woxsen isn't just about technology, it's about inspiring a generation of AI leaders who blend deep tech knowledge with entrepreneurial thinking and purpose-driven leadership. By embedding awareness, education, and innovation into every layer of this partnership, we are not only building smarter healthcare systems, but also empowering future changemakers.' The MoU was signed by Dr. Raul V. Rodriguez, Vice President of Woxsen University, and Mr. Affaan Shaikh, with oversight by Dr. Hemachandran K, Director of the AI Research Centre, and Mr. Khalid Shaikh, Advisor to IntelliDent AI. This milestone underscores IntelliDent AI's commitment to shaping global talent in healthcare AI and highlights Woxsen's ongoing mission to blend business, technology, and innovation through meaningful industry collaborations. Together, IntelliDent AI and Woxsen University are setting the foundation for impactful, future-forward education —where research, leadership, and real-world problem-solving converge.
Khaleej Times
a day ago
- Khaleej Times
Meet UAE's first Emirati female specialist in addiction treatment psychology
Ayesha Ameri has made history as the first Emirati woman to be officially recognised as a specialist in addiction treatment psychology. At just 30 years old, Aisha has dedicated the past nine years to her role at Erada Centre for Treatment and Rehabilitation, where she currently heads the psycho-social section in the rehabilitation department. Ayesha's passion for psychology began in high school, where she discovered her natural inclination for humanitarian work. "Volunteering and listening to others came naturally, which made psychology an easy choice," she told Khaleej Times. With a supportive family who believed in the power of therapy, she felt encouraged every step of the way. However, she initially hesitated to pursue addiction treatment due to the stigma associated with it. 'But meeting my first patient changed everything,' she recalled. 'I quickly realised how misunderstood people with addiction are, and I knew I had found my purpose.' This transformative experience drove her to specialise further, and Ayesha pursued a master's degree in Addiction Science. Completing her studies at Dubai Medical College significantly shaped her understanding of addiction as a complex bio-psycho-social disorder. 'The programme gave me a deeper, holistic understanding of addiction,' she explained, noting how her thesis sharpened her research skills and provided an evidence-based perspective that now informs her daily practice. Personal approach Ayesha's approach to treating addiction, clinically referred to as substance use disorder, is grounded in a personalised, evidence-based method. She centres her treatment around Cognitive Behavioral Therapy (CBT), which she finds most effective for addressing the psychological, social, and behavioural roots of addiction. 'Addiction is a complex disorder, and treatment needs to target all these aspects,' she said. Ayesha's triad CBT-based method, used in both group and individual settings, is unique in its adaptability. By incorporating regular screening tools, she can track each patient's progress and adjust the treatment to suit their specific challenges and strengths. Ayesha also believes that tackling the stigma surrounding addiction in Emirati society is crucial for progress. 'Addiction is a brain-based medical condition, not just a lack of willpower,' she emphasised. She advocates for raising awareness through schools, media, and healthcare campaigns, stressing the importance of a collective effort to change public perceptions. Support system in recovery In addition to medical treatment, Ayesha believes that family and community support play a pivotal role in the recovery process. 'It's important for families to understand that addiction is a disease, and recovery is not a linear journey,' she said. Ayesha encourages families to prepare for the challenges of recovery, advising them to maintain healthy boundaries while respecting the patient's confidentiality. 'Recovery works best when there is trust between the patient and therapist—and that trust can only grow when families support the process without being overly intertwined,' she noted. For young Emirati women aspiring to follow in her footsteps, Ayesha has a powerful message: 'The sky is the limit. There's a real need for more specialists in this field, whether in psychiatry, nursing, medicine, or mental health.' She credits the strong support she received throughout her career and is dedicated to offering that same encouragement to others who are eager to enter the field. Moreover, Ayesha underscores the importance of having more women represented in the field of addiction treatment psychology, particularly in the UAE. 'The UAE has been a strong advocate for women's empowerment, and I'm hopeful to see more women enter the field of addiction psychology,' she remarked. As the first licensed addiction psychologist in the UAE, Ayesha recognises the responsibility that comes with her role. 'For me, it's not just about breaking ground; it's about paving the way for others to follow.' In addition to her clinical work, Ayesha is involved in transformative projects at the Erada Centre aimed at addressing substance use disorder on a larger scale. 'We are collaborating with many different entities with the goal of 'not working in silos,'' she explained, feeling privileged to play a part in these ongoing and upcoming initiatives. Despite the emotional and mental demands of her work, Ayesha has learned to manage these challenges effectively. 'In the beginning, balancing the emotional demands of the work with everyday life was incredibly challenging,' she admitted. However, with experience, she has developed the ability to offer full empathy during sessions while maintaining her own mental space outside of work. Regular supervision with experienced professionals has been essential in helping her stay grounded, ensuring she provides the best care for her patients.
